Apama was founded to provide innovative solutions that address unmet
clinical needs in the treatment of AF.
Apama was founded to provide innovative solutions that address unmet
clinical needs in the treatment of AF.
We have gathered leaders in the med-tech industry to lead Apama in developing next generation AF ablation technology.
Amr Salahieh is a seasoned medical device entrepreneur with over 25 years of experience in the medical device industry. Amr is the founder of Shifamed LLC, a Silicon Valley based medical device incubator founded in 2009, from which Apama Medical, Maya Medical and Kalila Medical were formed. Maya Medical was sold to Covidien in 2012 for $230M and Kalila Medical was sold to Abbott in 2016. Prior to Shifamed, Amr co-founded Sadra Medical, a percutaneous aortic valve replacement company, which was sold to Boston Scientific for $450 million in January of 2011. Previously, as VP of R&D at Boston Scientific, Amr brought the FilterWire EX to the US market. He also played an active role in building EPI and in its acquisition by Boston Scientific. Amr has extensive R&D management experience stemming from his engineering consulting firm, Sobek Medical LLC which he sold to EPI, and from his work at CardioThoracic Systems and Guidant. Amr has also served as board member and advisor to a number of medical device companies including Atheromed Inc., SquareOne Inc., and TriReme Medical, Inc. Amr is either the inventor or co-inventor on >100 granted and >140 published US patent applications. He holds a B.S. in Biomedical Engineering and a B.S. in Electrical Engineering from Case Western Reserve University.
John joined Apama Medical as its Chief Financial Officer in May of 2015. He brings over 30 years of senior executive experience in the Life Sciences industry to the Company. Prior to joining Apama, John was the CFO at Access Closure, Inc. from 2007 to 2014, where he was responsible for all finance and accounting functions, corporate planning, tax, treasury operation, corporate development and risk management activities. During John’s tenure Access Closure grew from product launch into a profitable $80 million revenue business that today is one of the industry leaders in the vascular closure space. John was a key member of the deal team that transacted a sale of the Company to Cardinal Health (NYSE: CAH). Prior to joining AccessClosure, John was the CFO at Acologix, Inc., a biotechnology company focused on osteo-renal diseases. John has also advised several other private Silicon Valley startups in the healthcare space. John started his career at Ernst & Young LLP, where he worked for 16 years, most recently as a Partner and the Director of the Pacific Northwest Life Science Practice out of its Palo Alto, California office. John has extensive experience in both public and private company financings, having directly raised over $100 million in private debt and equity transactions, worked directly on over 25 IPO’s and numerous merger and acquisition transactions during the course of his career. John received his B.B.A. in Accounting from the University of Wisconsin––-Whitewater and is a Certified Public Accountant (inactive status).
Joann brings over 24 years of medical device experience in cardiovascular devices. Joann leads the R&D group as well as Clinical and Regulatory Affairs. She started her device career at Advanced Cardiovascular System/Guidant, where she worked in Manufacturing, R&D, and Sales over her fourteen years with the organization. As part of Guidant’s Manufacturing and R&D teams, she worked on dilatation products, bare metal stent design, and drug eluting stent. Joann was an early leader of the team at Guidant that developed the everolimus eluting coronary stent. Joann’s last position with Guidant was as a Field Clinical Representative for the Cardiac Rhythm Management group in Raleigh, North Carolina. Joann returned to R&D and continued advancing electrophysiology devices as part of Boston Scientific’s Electrophysiology group. Joann joined Shifamed and worked in the incubated companies in 2011. She followed one of the companies, Maya Medical and transitioned the product into Covidien Vascular. Joann returned to work on Apama in 2013. Joann received her mechanical engineering B.S. degree from Cal Poly, San Luis Obispo and M.S. from Stanford University. She holds nine issued U.S. patents.
PJ brings over fifteen years of experience developing and commercializing innovative medical devices in the electrophysiology, cardiac rhythm management, general surgery and thoracic surgery sectors. Most recently, PJ served as the Director of R&D for Cardica Inc., where he helped develop and launch the world’s first 5mm linear stapler. Prior to that, PJ has held numerous roles including R&D Manager at Stryker Endoscopy, Chief Clinical-Systems Engineer at St. Jude Medical CRMD, and Test Engineer at Boston Scientific Electrophysiology. PJ is a named inventor on 4 issued US patents and has several applications pending. PJ holds a B.S. in Biomedical Engineering from the University of California, San Diego, as well as an M.S. Eng. in Biomedical Devices from San Jose State University.
Jonah is Director of Design and co-founder of Apama Medical. Jonah has over 20 years of experience in designing innovative products in various industries. Other medical products Include: renal denervation device, steerable catheters, embolic protection device & percutaneous aortic valve. A former professional athlete, Jonah also started his own company designing and manufacturing sporting goods equipment with overseas manufacturing.
Between 2012 and 2015 Brian served as Vice President, Quality Assurance at BioCardia and had responsibility for quality system regulatory compliance and oversight of the operational and development quality engineering and manufacturing quality control functions. He was Director of Quality at Sadra Medical from 2008 until the company was acquired by Boston Scientific in 2011. Prior to that he served as Director of Quality Assurance and Regulatory Affairs at Apneon, which developed novel implantable therapies for sleep apnea, Director of Quality Assurance at Avantec Vascular/Intella, which developed and manufactured drug eluting stents, BMS and POBA systems, sheaths and guidewires, and Quality Systems Director for Cardima, which developed and manufactured minimally invasive, single-use, micro-catheter systems for cardiac ablation. Earlier in his career, he held management roles at Boston Scientific where he developed effective quality compliance strategies for the EP Technologies and IVUS groups, and Ford Motor Corporation where he provided leadership in the areas of operations, logistics and quality. He received a Master of Business Administration in Finance from St. Mary’s College of California and a Bachelor of Science in Aeronautical Engineering from Embry-Riddle Aeronautical University. Brian has over 20 years of experience in the areas of quality assurance and control, quality engineering and regulatory compliance, is named as inventor in several patents for implantable medical devices and delivery systems and is an American Society for Quality Certified Quality Engineer.
Adnan has over twenty-five years of experience in the medical device industry, in both monitoring and therapeutics. He has held several leadership roles in R&D and has been responsible for the development of multiple platform products. His areas of expertise include both technology-intensive capital products as well as high-volume disposables. Adnan is an inventor on 68 US patents issued or pending. He has a bachelor’s degree from the Indian Institute of Technology and an MS in mechanical engineering from the Ohio State University.
Carole joined Apama Medical in February 2016. Previously she was with Cardinal Health as the Director of HR for the Cordis cardiology business. Carole joined AccessClosure (acquired by CAH in 2014) in 2009 as Director of Human Resources and was promoted to Vice President in 2013. Carole brings nearly 20 years of HR experience in the medical device and drug delivery industries, with companies ranging in size from small, privately held to large public organizations. Prior to AccessClosure, Carole was Senior Manager of HR for Conor Medsystems with responsibility for the full HR function, and then spent over 2 years supporting the Cordis R&D organization following their acquisition of Conor in 2007. From 1997 to 2004, Carole was with ALZA Corporation in HRIS and compensation roles, including three years following ALZA’s acquisition by Johnson & Johnson. Carole holds a B.S. degree in Psychology from Cal Poly, San Luis Obispo and her SPHR certification.
Todd has over 15 years of regulatory experience in bringing medium and high risk medical devices to the global market within the vascular and ophthalmic industries. Most recently, Todd served as Director of Regulatory Affairs for Hansen Medical, where he led teams in achieving multiple key regulatory milestones that added value to the company prior to Hansen’s acquisition by Auris Surgical in July 2016. Prior to that, Todd held various regulatory roles at Covidien (following acquisition of Maya Medical), Thoratec, Abbott Vascular and Nidek. Before starting his career in regulatory affairs, Todd spent 10 years in Japan playing professional basketball. He holds a B.A. in Communication Studies from Vanderbilt University and a M.Ed. in Administration and Supervision from Tennessee State University.
Apama has assembled a seasoned board of directors to oversee the company and provide valuable insights based on proven industry experience.
Fred Khosravi is a Silicon Valley medical device entrepreneur who has co-founded eight medical companies and held senior management positions in both large and small enterprises. Fred is the Managing Director of Incept LLC a health sciences and technology development company. Incept has to-date, started the following companies: Confluent Surgical, Inc. (acquired in 2006 by Tyco Corporation), Embolic Protection, Inc. (acquired in 2001 by Boston Scientific Corporation), MarketRx, Inc., (acquired in 2007 by Cognizant Corporation), AccessClosure, Inc. (acquired in 2014 by Cardinal Health), Ostial Corp., Sadra Medical, Inc. (acquired in 2011 by Boston Scientific Corporation), Ocular Therapeutix, Inc., HotSpur, Inc. (acquired in 2012 by Telefex), Nextplane, Inc., and Claret Medical, Inc. In addition, Fred served on the boards of Kerberos Proximal Solutions, Inc. (acquired in 2006 by FoxHollow), dedicated to developing an innovative mechanical thrombectomy device for the vascular system, utilizing rinspiration=rinsing+aspiration and Advanced Stent Technologies, Inc. (acquired in 2004 by Boston Scientific Corporation), a development stage company focused on treatment of bifurcation vascular diseases. Fred was also Founder, Chairman and Chief Technical Officer of EndoTex Interventional Systems, Inc. (acquired in 2007 by Boston Scientific Corporation), a company in the carotid stent market.
Prior to his entrepreneurial career, Fred was Engineering Manager in the initial management team at Focal, Inc. (acquired by Genzyme), responsible for its cardiovascular products. He was also the Business Unit Manager of the Stent Business at Guidant/ACS where he led the initial design and development team of the highly successful Multilink stent. Prior to ACS (from 1986 through 1989) he held several management positions with Alcon Surgical Corp., developing pioneering small-incision intraocular lenses.
Fred is either the inventor or co-inventor on 95 granted and 79 published US patent applications. Fred has a B.S. degree in Mechanical Engineering, and graduated cum laude obtaining a Master of Science degree in Mechanical Engineering from Tennessee Tech University.
Tara Butler is a Managing Director at Ascension Ventures. Tara came to Ascension Ventures in 2002 after completing a residency in obstetrics and gynecology at Washington University in St. Louis. She primarily focuses on investments in the medical device and diagnostics sector. Tara has been a board member or observer at several Ascension Ventures portfolio companies, including Apama Medical, Augmenix, CHF Solutions, Confluent Surgical, CSA Medical, HemoSphere, Interventional Spine, ISTO Technologies, Ivantis, MindFrame, Neurolutions, Novasys, Ocular Therapeutix, OptiScan Biomedical, PathoGenetix, Stereotaxis (NASD:STXS), and TomoTherapy (NASD:TOMO). Prior to attending medical school, she held positions in business development at Medtronic, in finance at Honeywell and as a laboratory research assistant at the University of Pennsylvania School of Medicine. She holds a BS in Economics and an MBA from the Wharton School of Business at the University of Pennsylvania, and a Doctor of Medicine from the University of Pennsylvania School of Medicine. Tara keeps busy with her three children, but enjoys skiing and traveling whenever possible.
Gregory D. Casciaro has over 33 years of medical device experience, spanning, cardiovascular, surgical, and ortho-biologic sectors, and has held leadership positions in both public and private companies. Prior to joining the Apama Medical Board, Greg was President and CEO of AccessClosure, which was acquired by Cardinal Health in 2014. Prior to that, he was the President and CEO of XTENT Inc, (XTNT), a revolutionary drug-eluting stent platform. Prior to XTENT, Greg was the President and CEO of Orquest Inc., a private company manufacturing and selling bio-therapeutic products to the orthopedic market, which was acquired by DePuy Acromed, a division of Johnson and Johnson. Prior to that, he was President and CEO of General Surgical Innovations (GSII), which was acquired by US Surgical, a division of Tyco (TYC). He has held several senior level positions with Devices for Vascular Intervention, a division of Guidant Corporation (GDT), and North American Instrument Corporation. In addition to his operating roles, Greg is on the Board of Directors for Trireme Medical Inc, (which went public on the Singapore Catalyst Exchange as QTV) and Cardica (CRDC). Greg graduated from Marquette University in Milwaukee, WI with a B.A. in Business Administration.
Henry Chen is a Managing Partner at Delos Capital. Prior to establishing Delos in 2014, Henry was a Partner and Co-Head of Asia at Permira, a European private equity firm with global reach and a total committed capital of approximately €20bn. While at Permira, Henry Chen worked on a number of transactions including Asia Broadcast Satellite and Galaxy Entertainment Group. Prior to joining Permira in 2008, Henry spent nine years in Investment Banking at Goldman Sachs, where he was a Managing Director and co-headed the General Industrials Group, Asia (excluding Japan) which covered consumer retail, healthcare, industrials and transportation sectors. Prior to that, Henry was a corporate finance lawyer with Davis Polk in New York and Hong Kong. Mr. Chen holds Bachelor and Masters degrees from Harvard University, USA, and has a Juris Doctorate degree from Harvard Law School, USA.
Rob Kuhling is a Partner at ONSET Ventures. Rob came to ONSET Ventures in 1987 after experience in a variety of technology marketing, strategic development and management positions. Rob was Director of Marketing at Sun Microsystems, where he spearheaded the company’s expansion into the design automation marketplace. He also served as VP and Manager of General Electric-Calma’s $100 million electronic design automation business and was a team leader for Boston Consulting Group, where he oversaw the development of a range of corporate business strategies. At ONSET Ventures, Rob invests in communications and networking companies and medical device companies. Rob serves on the boards of several public and private companies, and has led ONSET Ventures’ investments in companies like Access Closure, Aneurx, Clarify, Conceptus, Alteon, Packeteer, Embolic Protection, Endotex Interventional Systems, and Gadzoox Networks. Rob’s current board memberships are Apama Medical, BAROnova, ClariPhy Communications, Neuronetics and Uptake Medical. Rob received his A.B. from Hamilton College and his MBA from Harvard Business School.
Amr Salahieh is a seasoned medical device entrepreneur with over 20 years of experience in the medical device industry. Amr is the founder of Shifamed LLC, a Silicon Valley based medical device incubator founded in 2009, from which Apama Medical, Maya Medical and Kalila Medical were formed. Prior to Shifamed, Amr co-founded Sadra Medical, a percutaneous aortic valve replacement company, raising $33 million in financing and leading the company to its first in-human milestone. Sadra Medical was sold to Boston Scientific for $450 million in January of 2011. Previously, as VP of R&D at Boston Scientific, Amr brought the FilterWire EX to the US market. He also played an active role in building EPI and in its acquisition by Boston Scientific.
Amr has extensive R&D management experience stemming from his engineering consulting firm, Sobek Medical LLC which he sold to EPI, and from his work at CardioThoracic Systems and Guidant. Amr has also served as board member and advisor to a number of medical device companies including Atheromed Inc., SquareOne Inc., and TriReme Medical, Inc. Amr is either the inventor or co-inventor on 94 granted and 131 published US patent applications. He holds a B.S. in Biomedical Engineering and a B.S. in Electrical Engineering from Case Western Reserve University.
Motasim Sirhan is CEO of Elixir Medical Corporation. He previously served as the CEO and Chairman of the board of directors for Avantec Vascular Corporation, which he founded in 1999 and it was acquired in 2002. Motasim was also co-founder of Maya Medical, a renal denervation company, which was acquired by Covidien in 2012. He held several senior positions at Guidant Corporation where he was responsible for generating over $2 billion in revenue for the company. He is either the inventor or co-inventor on 27 granted and 25 published US patent applications. In 1995, he was named by Silicon Valley Business Journal as one of thirty individuals under thirty who will play a leadership role in Silicon Valley’s future. In 1994, Harvard Business School selected one of his projects for a business case study. He holds an M.S. in Biomedical Engineering from the University of Texas at Dallas and Arlington, an M.S. in Engineering Management from the University of Southern California, and a dual B.S. degree in Biomedical and Electrical Engineering from the University of Southern California.
Results of AF-FICIENT, the first-in-man study which seeks to evaluate the safety and performance of the new Apama radiofrequency balloon catheter system, have shown the device is safe and allows successful pulmonary vein isolation for paroxysmal atrial fibrillation treatment.
Founded and led by serial entrepreneur Amr Salahieh, Apama Medical is developing a system that aims to combine the advantages of two approaches for treating atrial fibrillation: point-by-point radiofrequency-based ablation and cryoballoon ablation.
CAMPBELL, Calif., Nov. 17, 2016 — Apama Medical, Inc., a privately held medical device company committed to improving patient outcomes by developing a novel catheter ablation system for the underpenetrated atrial fibrillation (AF) market, today announced it has closed $13M in a Series C financing from existing investors Ascension Ventures, Medvance Incubator Partners, ONSET Ventures, Incept, LLC, and various angel investors, along with up to $6.5M in a debt facility with Silicon Valley Bank.
NEW ORLEANS, LA, – During the 2016 AHA conference, the Apama RF Balloon Catheter System was featured in a poster presentation submitted by Dr. Nitish Badhwar titled “Feasibility of a Visualization Radio Frequency Balloon Catheter for Epicardial Ablation”
NEW ORLEANS, LA, – During the 2016 AHA conference, the Apama RF Balloon Catheter System was featured in a poster presentation submitted by Dr. Byron Lee titled “Lesion Characteristics Using a Novel Multi-electrode Radiofrequency Balloon Ablation Catheter”
NICE, France, – During the CardioStim 2016 conference, the Apama RF Balloon Catheter System was featured in a poster presentation submitted by Dr. Ian Crozier titled “Initial Evaluation of a Novel Multi-Electrode Balloon Radio Frequency Ablation in Swine”
SAN FRANCISCO, Calif., – During the HRS 2016 conference, the Apama RF Balloon Catheter System was featured in a poster presentation submitted by Dr. Amin Al-Ahmad titled “Radio Frequency Ablation in the Porcine Model using a Multi-Electrode Balloon Catheter”
CAMPBELL, Calif., — Apama Medical, Inc., a privately held medical device company focused on the development of next-generation atrial fibrillation technologies, today announced raising $11.0M in the first tranche of its $17.5M Series B financing. Apama Medical is a portfolio company incubated out of Shifamed, LLC.
CAMPBELL, Calif., — Shifamed LLC, a medical technology incubator, announced today that Apama Medical, Inc., one of its privately held portfolio companies, has raised $3.2M in Series A-1 financing.
CAMPBELL, Calif., — Apama Medical, a privately held medical device company focused on the development of next-generation atrial fibrillation technologies, today announced the issuance of U.S. Patent No. 8295902 by the US Patent and Trademark Office (USPTO), titled “Low Profile Electrodes”. The patent encompasses low profile electrode assemblies for use on expandable structures such as balloons used in endovascular ablation or other surgical procedures.
Our team shares a passion for developing innovative technologies that improve patients’ lives. If you are seeking a dynamic environment where you can make a real impact, Apama may be a good fit for you.
All of our positions are currently filled, but we are always happy to receive resumes from great candidates. Please contact firstname.lastname@example.org.
Note: Principals only. No third party referrals will be accepted without prior approval by Apama Medical. As a general practice, Apama Medical does not accept unsolicited resumes or placement information from any individual or agency that supplies candidates for a fee.